Notably, IGFBP-7 enhances the sensitivity of AML cells to chemotherapy, with higher expression levels correlating with better patient prognosis, indicating its positive role in AML treatment and outcomes (183, 184), while IGFBP-5 reduces cell proliferation and enhances chemotherapy efficacy by inhibiting the IGF-IR/AKT signaling pathway (185). The gene discussed is IGFBP5; the disease is acute myeloid leukemia.